Trial Profile
A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females With Polycystic Ovary Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pavinetant (Primary)
- Indications Polycystic ovary syndrome
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 01 Nov 2016 Results published in the Journal of Clinical Endocrinology and Metabolism
- 27 Jul 2016 Results published in a Millendo Therapeutics media release.
- 27 Jul 2016 Primary endpoint (Change from baseline at Day 7 in Luteinizing hormone AUC(0-8)) has been met, according to a Millendo Therapeutics media release.